Carotid Stenting Makes a Strong Showing in the CREST-2 Registry
Very low stroke/death rates reassure about the quality of stenting in the ongoing CREST-2 trial, a researcher says.
Related Articles
The Cardiovascular Consequences of War
For both civilians and military veterans, war destroys health infrastructure and has profound effects on CV risk factors.
The Cardiovascular Consequences of War
For both civilians and military veterans, war destroys health infrastructure and has profound effects on CV risk factors.
The Cardiovascular Consequences of War
For both civilians and military veterans, war destroys health infrastructure and has profound effects on CV risk factors.
Coronary Calcium Scoring May Help Get Semaglutide to Highest-Risk Patients
It’s not just about the GLP-1 drug: CTA could be used to guide any number of CV prevention therapies, Maros Ferencik says.
Coronary Inflammation Highest in Socioeconomically Deprived Areas: ORFAN
The findings suggest a “potential therapeutic target” in the quest to reduce inequities in cardiac risk, a researcher says.
FDA to Add New Diversity Requirements for Certain Clinical Studies
Requiring sponsors to submit diversity action plans is a good first step to greater representation in trials, experts say.
Going Global: Asia-Pacific Region Not Represented in Large Clinical Trials
There’s a need to expand the reach of clinical trials, especially to the Asia-Pacific region, home to a heavy burden of CV disease.
Coronary Calcium Scoring May Help Get Semaglutide to Highest-Risk Patients
It’s not just about the GLP-1 drug: CTA could be used to guide any number of CV prevention therapies, Maros Ferencik says.
Aspirin for Primary Prevention of CVD Remains Common in US
Negative RCTs and new recommendations sparked some decline, but many adults are still reaching for their daily pill.
Coronary Inflammation Highest in Socioeconomically Deprived Areas: ORFAN
The findings suggest a “potential therapeutic target” in the quest to reduce inequities in cardiac risk, a researcher says.